Press Releases Latest Dec 06, 2021 Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV Press Releases Year None202120202019201820172016201520142013 Mar 24, 2021 Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Mar 20, 2021 Theratechnologies Announces New Data Demonstrating Tesamorelin’s Positive Effect On Immune Response Linked To Liver Inflammation Mar 10, 2021 Theratechnologies Announces Two E-Posters on TH1902 To Be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021 Feb 25, 2021 Theratechnologies to Present at the H.C. Wainwright Global Life Sciences Conference Feb 25, 2021 Theratechnologies Announces Fourth-Quarter And Fiscal-Year 2020 Financial Results Feb 11, 2021 Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2020 Feb 04, 2021 Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers Jan 19, 2021 Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option Jan 15, 2021 Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version) First page « Previous page ‹ Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 31 - 40 of 268
Dec 06, 2021 Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV
Mar 24, 2021 Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors
Mar 20, 2021 Theratechnologies Announces New Data Demonstrating Tesamorelin’s Positive Effect On Immune Response Linked To Liver Inflammation
Mar 10, 2021 Theratechnologies Announces Two E-Posters on TH1902 To Be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021
Feb 04, 2021 Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers
Jan 19, 2021 Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
Jan 15, 2021 Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference
Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version)
